ScholarLens Back to search
2021•International Journal of Radiation Oncology*Biology*PhysicsOpen access

SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation

Rafał Dziadziuszko, Myung‐Ju Ahn, Karen Kelly, Sanjay Popat, Heather A. Wakelee, Anne‐Marie Baird, Isabelle Rooney, M. Afshari, S. Coleman, Z Zhang, H. Kiruki, N. Patil, Xiaohui Wen, Jeffrey D. Bradley

Open full text 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Atezolizumab, Durvalumab, Medicine, Oncology, Internal medicine, Avelumab, Pembrolizumab, Nivolumab

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation — Research Paper | ScholarLens